Last updated on August 2019

A Research Study to Compare Semaglutide to Insulin Aspart When Taken Together With Metformin and Insulin Glargine in People With Type 2 Diabetes


Brief description of study

This study will compare the effect of semaglutide once weekly to insulin aspart 3 times daily as add on to metformin and insulin glargine in people with type 2 diabetes. Participants will either get insulin glargine and semaglutide or insulin glargine and insulin aspart - which treatment the participant get is decided by chance. Insulin glargine is taken once a day and semaglutide once a week. Insulin aspart is taken three times per day before a meal. All three medicines come in pre-filled pens for injection under the skin. The study will last for about 71 weeks. If participant's blood sugar gets under or over certain values participant will only participate in 14 weeks. The study doctor will inform the participant about this. The participant will have 15 clinic visits and 22 phone calls with the study doctor.

Clinical Study Identifier: NCT03689374

Find a site near you

Start Over

Novo Nordisk Investigational Site

Banja Luka, Bosnia and Herzegovina
  Connect »

Novo Nordisk Investigational Site

Sarajevo, Bosnia and Herzegovina
  Connect »

Novo Nordisk Investigational Site

Tuzla, Bosnia and Herzegovina
  Connect »

Novo Nordisk Investigational Site

Skopje, Macedonia, The Former Yugoslav Republic of
  Connect »